Warren B. Learmonth
Warren B. Learmonth
(604) 640-4166
(604) 622-5866
200 Burrard St, Suite 1200, Waterford Centre, Vancouver, BC
Year called to bar: 1996 (BC)
Warren Learmonth is a partner in the BLG Vancouver office. He provides expertise to clients in securities and corporate law. Within his practice, he acts as counsel to companies, investment bankers, and board special committees in corporate finance, mergers & acquisitions, and restructuring transactions. His clients are involved in biotechnology, e-business, financial services, and forestry and mining, among others. Warren also advises public corporations and their boards of directors, with an emphasis on regulatory compliance, corporate governance, directors’ duties and responsibilities, and transaction structuring. Additionally, Warren works with both private and public companies on the adoption of securities-based executive compensation plans. He is recognized in the 2021 edition of The Best Lawyers in Canada for Securities Law (since 2013), Corporate Law (since 2014), and Mergers & Acquisitions Law (since 2019). Warren is also recognized in the 2020 edition of Lexpert® Special Edition — Agribusiness and Cannabis, the 2020 and previous editions of Lexpert® Special Edition — Global Mining, the 2020 (and since 2011) editions of The Canadian Legal Lexpert® Directory (Private Equity), and the 2020 edition (Corporate Finance & Securities, Corporate Mid-Market).
Warren B. Learmonth is a featured Leading Lawyer in:
Warren B. Learmonth is also listed in the following publication(s)
Read more about Warren B. Learmonth in ...
On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute US$37.5 million in transaction-related seed capital for Genevant.